Drug Trial Radar · NCT02460224
Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.
Last checked: Nov 20, 2026Latest source record: Feb 10, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
490
Actual
Start
Jun 17, 2015
Primary completion
Dec 31, 2020
Study completion Dec 31, 2020
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Jun 2, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study was to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and anti-tumor activity of LAG525 as a single agent and in combination with PDR001 to adult patients with solid tumors. The study consists of a dose escalation (phase 1) to determine the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) for LAG525 as a single agent and in combination with PDR001, and a dose expansion (phase 2) which characterized treatment of LAG525 in combination with PDR001 at the MTD or RP2D.
Conditions
- Advanced Solid Tumors
Interventions
LAG525Drug
LAG525 was administered via intravenous (i.v.) infusion
PDR001Drug
PDR001 was administered via i.v. infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1: Number of Participants With Dose-Limiting Toxicities (DLTs)Time frame: 15 days for single-agent LAG525 arms and 30 days for the combination LAG525 + PDR001 arms
- Phase 2: Overall Response Rate (ORR) Per RECIST 1.1Time frame: From start of treatment until end of treatment, assessed up to 2.6 years
Locations
24 sites in 12 countries. Site status is shown where the registry gives one.
Columbia University Medical Center SC LAG X2101C
New York, New York
Memorial Sloan Kettering Cancer Center SC
New York, New York
Duke Clinical Research Institute SC
Durham, North Carolina
University of Texas MD Anderson Cancer Center
Houston, Texas
Cancer Therapy and Research Center UT Health Science Center CTRC 2
San Antonio, Texas
Huntsman Cancer Institute Huntsman Cancer Institute
Salt Lake City, Utah
Novartis Investigative Site
Westmead, New South Wales, Australia
Novartis Investigative Site
Heidelberg, Victoria, Australia
Novartis Investigative Site
Leuven, Belgium
Novartis Investigative Site
Edmonton, Alberta, Canada
Novartis Investigative Site
Toronto, Ontario, Canada
Novartis Investigative Site
Lyon, France
Novartis Investigative Site
Saint-Herblain Cédex, France
Novartis Investigative Site
Heidelberg, Germany
Novartis Investigative Site
Würzburg, Germany
Novartis Investigative Site
Hong Kong, Hong Kong
Novartis Investigative Site
Milan, MI, Italy
Novartis Investigative Site
Modena, MO, Italy
Novartis Investigative Site
Fukuoka, Fukuoka, Japan
Novartis Investigative Site
Singapore, Singapore
Novartis Investigative Site
Singapore, Singapore
Novartis Investigative Site
Madrid, Spain
Novartis Investigative Site
Barcelona, Catalonia, Spain
Novartis Investigative Site
Taipei, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.